摘要
目的:了解浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的临床应用情况。方法:回顾性分析浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的使用数据,包括销售金额、用药频度(DDDs)、日均费用(DDC)等。结果:浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的销售金额由2 530 192.33元增长至6 201 691.54元,在药品总销售金额中的占比由13.93%上升至17.40%,均呈上升趋势。阿那曲唑的销售金额各年度均排名首位。他莫西芬、阿那曲唑和来曲唑的DDDs各年度均排名前3位。DDC各年度排名首位的是戈舍瑞林。结论:浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物处方量及销售金额都呈逐年增长趋势;安全有效、经济方便的药物在临床使用中占优势。
OBJECTIVE： To investigate the status quo and tendency of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015. METHODS： The prescriptions of breast cancer patients in 11 hospitals of Zhe- jiang province were analyzed retrospectively in respects of consumption sum, DDDs, DDC, etc. RESULTS： The consumption sum of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015 increased from 2 530 192.33 yuan to 6 201 691.54 yuan, and its proportion in total consumption sum increased from 13.93% to 17.40%, showing in- creasing tendency. The anastrozole always took up the first place in the list of consumption sum. Tamoxifen, anastrozole and letro- zole took up the top 3 places in the list of DDDs. Goserelin took up the first place in the list of DDC. CONCLUSIONS： The pre- scription amount and consumptionsum of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015 show year-on-year growth trend; and those drugs which are safe, effective, economical and convenient predomi- nate in clinic.
出处
《中国药房》
CAS
北大核心
2017年第26期3620-3623,共4页
China Pharmacy
